Zenas Biopharma, INC

Zenas BioPharma reported Q1 2026 financial results, highlighting progress in its autoimmune disease pipeline and extended cash runway into 2029.

Zenas BioPharma, Inc. successfully completed a public offering of $200 million in convertible senior notes and 5 million shares of common stock, raising approximately $287.4 million to fund its pipeline and potential product launch.

Zenas BioPharma announced its Q4 and full-year 2025 financial results, highlighted by positive Phase 3 obexelimab data and a new $250 million debt facility.

Zenas BioPharma, Inc. has approved an Amended and Restated Short-Term Incentive Plan, effective January 1, 2026, to enhance employee motivation and retention through performance-based cash bonuses.

Zenas BioPharma announced positive Phase 3 trial results for obexelimab in IgG4-RD, paving the way for regulatory submissions and extending its cash runway through 2026.

Zenas BioPharma's Board approved a new 2026 Inducement Plan, authorizing up to 1,000,000 shares for new employee equity awards without shareholder approval.

Zenas BioPharma, Inc. files a Form 10-Q detailing its first quarter 2026 financial results, including an amendment to its Revenue Participation Right Purchase and Sale Agreement and significant financing activities.

Zenas BioPharma reports increased Q3 2025 net losses and significant cash burn, while advancing its immunology pipeline and securing new financing.

Zenas BioPharma reported increased net losses in Q2 2025 as it significantly ramped up research and development spending for its lead immunology programs, while securing new licensing revenue.

Zenas BioPharma reports a net loss of $33.6 million for Q1 2025, but recognizes $10 million in license and collaboration revenue.

Zenas BioPharma reports a net loss of $38.6 million for the third quarter of 2024, driven by increased research and development expenses, following its recent IPO.

Zenas BioPharma announced positive Phase 3 results for obexelimab in IgG4-RD and promising Phase 2 RMS data, while reporting significant net losses and a going concern warning from its auditor.

Zenas BioPharma details its 2024 financial performance, highlighting ongoing clinical trials and strategic collaborations in the immunology space.

Director Jason Nunn was granted 18,500 stock options in Zenas BioPharma, Inc. with an exercise price of $18.71.

Director Lu Hongbo was granted 18,500 stock options in Zenas BioPharma, Inc. with an exercise price of $18.71.

Zenas BioPharma CEO Leon O. Moulder Jr. was granted 500,000 stock options with an exercise price of $18.71.

Director John J. Orloff was granted 18,500 stock options in Zenas BioPharma, Inc. with an exercise price of $18.71.

Lisa von Moltke, Head of R&D and CMO of Zenas BioPharma, was granted 150,000 stock options with an exercise price of $18.71.

Director Patricia L. Allen was granted 18,500 stock options in Zenas BioPharma, Inc. as part of a standard equity compensation plan.

Zenas BioPharma, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on May 11, 2026, to elect directors and ratify its independent auditor.

Zenas BioPharma announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, with key proposals including the election of directors and ratification of the company's accounting firm.

Zenas BioPharma announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, featuring director elections and ratification of the company's auditor.

Zenas BioPharma is increasing its IPO offering size by registering additional shares worth approximately $28.8 million, including an option for underwriters to purchase more shares.

Zenas BioPharma, a clinical-stage biopharmaceutical company, is seeking to raise $180.7 million through an initial public offering to advance its immunology-based therapies.

Zenas BioPharma amends its license agreement with Xencor and files an S-1 registration statement for an initial public offering of its common stock.

Leon O. Moulder, Jr., CEO of Zenas BioPharma, along with affiliated entities, has disclosed beneficial ownership of 5.09% of the company's common stock.

Leon O. Moulder, Jr. and associated entities report a combined 4.79% stake in Zenas BioPharma following recent share acquisitions.

Zenas BioPharma's CEO and Chairman, Leon O. Moulder, Jr., along with affiliated entities, reported an aggregate beneficial ownership of 5.159% of the company's common stock, following recent open-market purchases and a private placement.

Enavate Sciences and Zebra Aggregator increased their beneficial ownership in Zenas BioPharma to 7.3% following participation in a $120 million private placement.

SR One Capital Management and affiliated funds increased their beneficial ownership in Zenas BioPharma, Inc. to 9.4% through a recent private placement.

Longitude Capital and its affiliates, along with director Patrick Enright, reported a decrease in their beneficial ownership of Zenas BioPharma to below 5% following a recent private placement.

FMR LLC and Abigail P. Johnson have disclosed a 14.3% beneficial ownership stake in Zenas Biopharma Inc. common stock as of December 31, 2025.

Novo Holdings A/S, a Danish investment firm, has disclosed a 4.7% beneficial ownership stake in Zenas BioPharma, Inc. common stock.

InnoCare Pharma Inc. and its affiliates have reported a 9.4% beneficial ownership stake in Zenas BioPharma, Inc., totaling 5,000,000 shares of common stock.

FMR LLC and Abigail P. Johnson have reported an 11.0% beneficial ownership stake in Zenas BioPharma Inc.'s common stock as of August 29, 2025.

FMR LLC and Abigail P. Johnson reported a 7.9% beneficial ownership stake in Zenas Biopharma Inc. as of June 30, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 6.8% of Zenas BioPharma Inc.'s common stock as of March 31, 2025.